Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment.

Schizophrenia research - 15 Sept 2005

Bishop Jeffrey R, Ellingrod Vicki L, Moline Jessica, Miller Del

Abstract excerpt

PURPOSE: The excitatory neurotransmitter glutamate has become an important area of focus for schizophrenia researchers. Polymorphisms in the type-three metabotropic glutamate receptor gene (GRM3) have been associated with the pathogenesis of schizophrenia. The purpose of this study was to determine whether a pharmacogenetic relationship exists between six polymorphisms of GRM3 and clinical improvement during...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Benzodiazepines
Share to Linear Models

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Olanzapine

Share to Receptors, Metabotropic Glutamate

Share to Schizophrenia

Share to Schizophrenic Psychology

Share to Treatment Outcome

Source

Identifiers

PMID: 15913960
DOI: 10.1016/j.schres.2005.04.001

Genes

GRM3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment.PMID 15913960Read ↗

Further evidence for a functional role of the glutamate receptor gene GRM3 in schizophrenia.Semantic proximity Read ↗

Positive associations of polymorphisms in the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia.Semantic proximity Read ↗

Association between type-three metabotropic glutamate receptor gene (GRM3) variants and symptom presentation in treatment refractory schizophrenia.Semantic proximity Read ↗

Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder.Semantic proximity Read ↗

Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia.Semantic proximity Read ↗

Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophrenia.Semantic proximity Read ↗

Synergistic association of PI4KA and GRM3 genetic polymorphisms with poor antipsychotic response in south Indian schizophrenia patients with low severity of illness.Semantic proximity Read ↗

5-HT2A receptor promoter polymorphism, -1438G/A and negative symptom response to olanzapine in schizophrenia.Semantic proximity Read ↗

Meta-analysis supports GWAS-implicated link between GRM3 and schizophrenia risk.Semantic proximity Read ↗

No evidence for association between polymorphisms in GRM3 and schizophrenia.Semantic proximity Read ↗

Association study of GRM7 polymorphisms and schizophrenia in the Chinese Han population.Semantic proximity Read ↗

Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.